Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

STOK

Stoke Therapeutics Inc

Dec 11 • 04:00PM ET

12.98

Dollar change -0.28
Percentage change -2.11	%

Healthcare • Biotechnology • USA • NASD

Peers: SRPT PTCT FOLD RARE NTLA CRSP EDIT ARWR VRTX ALNY

| Held by: VTI IWM XBI VXF IWO SCHA VTWO DFAC DFAS VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.10	Insider Own	22.64%	Shs Outstand	52.94M	Perf Week	1.33%
Market Cap	687.51M	Forward P/E	-	EPS next Y	-2.50	Insider Trans	-14.62%	Shs Float	40.98M	Perf Month	-6.01%
Income	-105.46M	PEG	-	EPS next Q	-0.55	Inst Own	92.35%	Short Float	16.43%	Perf Quarter	-5.32%
Sales	16.74M	P/S	41.07	EPS this Y	14.35%	Inst Trans	-7.30%	Short Ratio	11.01	Perf Half Y	-24.49%
Book/sh	4.38	P/B	2.96	EPS next Y	-22.60%	ROA	-39.56%	Short Interest	6.73M	Perf Year	165.98%
Cash/sh	4.52	P/C	2.87	EPS next 5Y	-	ROE	-52.06%	52W Range	4.09 - 17.58	Perf YTD	146.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-44.06%	ROI	-44.85%	52W High	-26.17%	Beta	0.93
Dividend TTM	-	Quick Ratio	5.09	Sales past 5Y	-5.84%	Gross Margin	72.83%	52W Low	217.36%	ATR (14)	0.83
Dividend Ex-Date	-	Current Ratio	5.09	EPS Y/Y TTM	13.54%	Oper. Margin	-700.61%	RSI (14)	53.86	Volatility	7.49% 6.60%
Employees	110	Debt/Eq	0.02	Sales Y/Y TTM	81.04%	Profit Margin	-629.86%	Recom	1.22	Target Price	22.29
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	15.39%	Payout	-	Rel Volume	0.46	Prev Close	13.26
Sales Surprise	27.83%	EPS Surprise	9.62%	Sales Q/Q	47.94%	Earnings	Nov 05 BMO	Avg Volume	611.84K	Price	12.98
SMA20	5.07%	SMA50	4.00%	SMA200	1.31%	Trades		Volume	283,006	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-14-24	Resumed	Leerink Partners	Outperform	$18
Mar-26-24	Upgrade	TD Cowen	Market Perform → Outperform
Nov-20-23	Resumed	JP Morgan	Neutral
Jul-25-23	Downgrade	TD Cowen	Outperform → Market Perform
May-01-23	Upgrade	BofA Securities	Underperform → Neutral	$9 → $12
Apr-26-23	Resumed	Canaccord Genuity	Buy	$24
Jan-06-23	Downgrade	BofA Securities	Buy → Underperform	$22 → $9
Oct-24-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$30
Jan-31-22	Initiated	Jefferies	Buy	$50
Dec-03-21	Initiated	BofA Securities	Buy	$43
Nov-22-21	Upgrade	JP Morgan	Neutral → Overweight	$41
May-18-21	Initiated	UBS	Neutral	$35
May-10-21	Upgrade	Wedbush	Neutral → Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform	$58
Feb-10-21	Downgrade	Wedbush	Outperform → Neutral
Dec-15-20	Resumed	H.C. Wainwright	Buy	$70
Dec-11-20	Reiterated	Needham	Buy	$48 → $56
Oct-23-20	Initiated	Cantor Fitzgerald	Overweight	$49
Sep-29-20	Resumed	JP Morgan	Neutral	$34
Sep-29-20	Initiated	Needham	Buy	$42

Show Previous Ratings

Dec-06-24 12:00PM	Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire) +5.57%
Dec-05-24 08:30AM	GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners (Business Wire)
Dec-04-24 07:00AM	Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome (Business Wire) +12.07%
Dec-02-24 08:00AM	Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting (Business Wire)
Nov-26-24 01:56AM	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond (Pharma Voice)
09:55AM	Loading…
Nov-20-24 09:55AM	Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-08-24 09:55AM	Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade (Zacks)
Nov-05-24 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire)
Oct-29-24 10:01AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-12-24 06:10PM	Stoke Therapeutics assumed with an Outperform at Leerink (TipRanks)
10:18AM	Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases (Insider Monkey)
Sep-23-24 07:07PM	Skorpios Trust Reduces Stake in Stoke Therapeutics Inc (GuruFocus.com)
Sep-10-24 07:00AM	Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome (Business Wire)
Sep-04-24 08:00AM	Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer (Business Wire)
08:00AM	Loading…
Sep-03-24 08:00AM	Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome (Business Wire)
08:00AM	Stoke Therapeutics to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Aug-08-24 06:53AM	Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold (Clinical Trials Arena)
Aug-07-24 08:25AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Jul-16-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -7.19%
Jun-18-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-24 09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
Jun-03-24 04:30PM	Stoke Therapeutics to Present at Upcoming Investor Conferences in June (Business Wire) +5.88%
May-22-24 07:07PM	Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares (GuruFocus.com) -6.96%
May-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +15.83%
May-07-24 09:04PM	Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ... (GuruFocus.com)
10:30AM	Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating (MT Newswires)
May-06-24 11:53AM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:05AM	Loading…
08:05AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
Apr-29-24 10:21AM	Stoke Therapeutics Appoints Thomas Leggett CFO (MT Newswires)
08:00AM	Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer (Business Wire)
Apr-25-24 10:01AM	Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline (Zacks)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-17-24 08:00AM	Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer (Business Wire) -5.86%
Apr-04-24 04:30PM	Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference (Business Wire) -5.03%
Mar-27-24 11:40PM	Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering (Business Wire) +37.71%
08:50AM	Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data (Zacks)
Mar-26-24 04:07PM	Stoke Therapeutics Announces Proposed Public Offering (Business Wire) +58.31%
11:20AM	Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients (Benzinga)
07:54AM	Why Is Stoke Therapeutics (STOK) Stock Up 99% Today? (InvestorPlace)
07:49AM	Stoke shares surge on updated results for Dravet drug (BioPharma Dive)
Mar-25-24 09:53PM	STOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:10PM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
04:01PM	Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome (Business Wire)
Feb-29-24 08:50AM	Why Earnings Season Could Be Great for Stoke Therapeutics (STOK) (Zacks)
Feb-26-24 10:00AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) +11.95%
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-19-24 02:31PM	Triple Threat: 3 Stocks to Buy for 3X Upside Potential (InvestorPlace)
Feb-15-24 09:55AM	Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect? (Zacks)
06:59AM	Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar? (Zacks)
Jan-17-24 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jan-08-24 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024 (Business Wire)
Jan-04-24 04:30PM	Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-02-24 10:29AM	Why healthcare, biotech may be top plays for 2024: BTIG (Yahoo Finance Video) +11.41%
Dec-14-23 09:55AM	Wall Street Analysts Predict a 220.81% Upside in Stoke Therapeutics, Inc. (STOK): Here's What You Should Know (Zacks)
Dec-01-23 09:00AM	Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting (Business Wire)
Nov-21-23 08:00AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting (Business Wire) -6.47%
Nov-09-23 05:48AM	Stoke Therapeutics Inc (STOK) Reports Q3 Financial Results and Progress in Dravet Syndrome Treatment (GuruFocus.com)
Nov-07-23 07:00AM	Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates (Business Wire) +12.53%
Oct-17-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) -6.80%
Sep-21-23 08:00AM	Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference (Business Wire) -6.53%
Sep-20-23 04:30PM	Stoke Therapeutics Appoints Ian Smith to its Board of Directors (Business Wire) -6.72%
Sep-05-23 07:00AM	Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress (Business Wire)
Aug-16-23 01:00PM	This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street (Motley Fool)
Aug-08-23 06:02AM	Stoke Therapeutics Second Quarter 2023 Earnings: Misses Expectations (Simply Wall St.) -5.13%
Aug-07-23 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (Business Wire)
Jul-25-23 02:32PM	Why Shares of Stoke Therapeutics Plummeted Tuesday (Motley Fool) -32.11%
07:00AM	Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome (Business Wire)
Jul-21-23 07:30AM	Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome (Business Wire) +7.73%
Jul-05-23 01:20PM	Here's Why We're Not Too Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation (Simply Wall St.)
Jun-21-23 04:22AM	Stoke Therapeutics, Inc. (STOK) Surges 6.3%: Is This an Indication of Further Gains? (Zacks)
Jun-16-23 04:30PM	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire) +6.31%
Jun-14-23 09:55AM	Should You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross? (Zacks)
May-09-23 09:55AM	How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 102.91% (Zacks)
06:04AM	New Forecasts: Here's What Analysts Think The Future Holds For Stoke Therapeutics, Inc. (NASDAQ:STOK) (Simply Wall St.)
May-06-23 08:03AM	Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Boosting Their Estimates (Simply Wall St.)
May-04-23 10:00AM	Analysts Estimate Synlogic, Inc. (SYBX) to Report a Decline in Earnings: What to Look Out for (Zacks) +12.96%
08:55AM	Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates (Business Wire)
May-03-23 08:00AM	Stoke Therapeutics to Present at the BofA Securities Health Care Conference (Business Wire)
May-02-23 10:02AM	Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-25-23 07:00AM	Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom (Business Wire)
Mar-28-23 10:40AM	Investors in Stoke Therapeutics (NASDAQ:STOK) have unfortunately lost 64% over the last three years (Simply Wall St.)
Mar-15-23 07:00AM	Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome (Business Wire) -6.92%
Mar-06-23 08:15AM	Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Business Wire)
Feb-27-23 04:30PM	Stoke Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire)
Feb-07-23 08:00AM	Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Jan-26-23 05:59AM	Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023 (Business Wire)
Jan-04-23 08:00AM	Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire) +6.16%
Dec-02-22 09:00AM	Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting (Business Wire)
Nov-29-22 07:30AM	Stoke Therapeutics to Present Data from the Companys Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting (Business Wire)
Nov-14-22 01:02PM	Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program (Benzinga) -25.30%

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 09 '24	Sale	12.99	2,586	33,596	44,746	Dec 11 04:07 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 09 '24	Sale	13.61	13,666	185,978	21,476	Dec 11 04:05 PM
Kaye Edward M. MD	CEO	Dec 09 '24	Sale	12.99	6,786	88,158	61,885	Dec 11 04:04 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 06 '24	Sale	12.78	13,945	178,182	47,332	Dec 10 07:02 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 06 '24	Sale	12.78	9,696	123,891	35,142	Dec 10 07:01 PM
Kaye Edward M. MD	CEO	Dec 06 '24	Sale	12.78	6,170	78,837	68,671	Dec 10 07:00 PM
JONATHAN ALLAN	Officer	Dec 09 '24	Proposed Sale	13.27	12,114	160,753		Dec 09 04:48 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 03 '24	Option Exercise	0.00	6,000	0	44,838	Dec 05 04:21 PM
Kaye Edward M. MD	CEO	Dec 03 '24	Option Exercise	0.00	26,500	0	75,091	Dec 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 03 '24	Option Exercise	0.00	10,000	0	61,277	Dec 05 04:19 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Dec 01 '24	Option Exercise	0.00	33,927	0	38,838	Dec 03 04:14 PM
Kaye Edward M. MD	CEO	Dec 01 '24	Option Exercise	0.00	21,591	0	48,591	Dec 03 04:13 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '24	Option Exercise	0.60	10,000	6,000	61,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 01 '24	Option Exercise	0.00	48,792	0	51,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Dec 02 '24	Sale	12.07	10,000	120,698	51,277	Dec 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Nov 05 04:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Nov 01 '24	Sale	12.68	10,000	126,803	2,485	Nov 05 04:15 PM
BARUCH TICHO	Officer	Nov 01 '24	Proposed Sale	12.36	20,000	247,200		Nov 01 04:50 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Oct 02 04:07 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Oct 01 '24	Sale	12.06	10,000	120,648	2,485	Oct 02 04:07 PM
Skorpios Trust	10% Owner	Sep 19 '24	Sale	14.05	1,937,500	27,221,875	8,906,181	Sep 23 04:23 PM
Blue Horizon E LTD	Affiliate	Sep 19 '24	Proposed Sale	15.22	1,937,500	29,488,750		Sep 19 05:23 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 03 '24	Option Exercise	0.60	10,000	6,000	12,485	Sep 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Sep 03 '24	Sale	14.95	10,000	149,481	2,485	Sep 05 04:20 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Aug 05 04:09 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Aug 01 '24	Sale	14.58	10,000	145,843	2,485	Aug 05 04:09 PM
BARUCH TICHO	Officer	Aug 01 '24	Proposed Sale	14.97	30,000	449,100		Aug 01 04:25 PM
Nash Huw M.	Chief Business Officer	Jul 02 '24	Sale	13.11	2,500	32,779	0	Jul 03 04:13 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '24	Option Exercise	0.60	10,000	6,000	12,485	Jul 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jul 01 '24	Sale	13.75	10,000	137,458	2,485	Jul 03 04:11 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '24	Option Exercise	0.60	10,000	6,000	12,485	Jun 05 04:18 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Jun 03 '24	Sale	15.22	10,000	152,185	2,485	Jun 05 04:18 PM
Nash Huw M.	COO & CBO	May 20 '24	Option Exercise	0.40	50,000	20,000	50,000	May 22 04:20 PM
Nash Huw M.	COO & CBO	May 20 '24	Sale	15.39	50,000	769,500	0	May 22 04:20 PM
Kaye Edward M. MD	CEO	May 20 '24	Sale	15.43	42,350	653,529	27,000	May 22 04:17 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	May 20 '24	Option Exercise	7.07	8,599	60,795	11,197	May 22 04:15 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	May 20 '24	Sale	15.04	8,599	129,327	2,598	May 22 04:15 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '24	Option Exercise	0.60	10,000	6,000	12,485	May 03 04:24 PM
Ticho Barry	CHIEF MEDICAL OFFICER	May 01 '24	Sale	11.37	10,000	113,653	2,485	May 03 04:24 PM
Skorpios Trust	10% Owner	Apr 17 '24	Sale	11.60	3,600,000	41,760,000	10,843,681	Apr 18 04:16 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '24	Option Exercise	0.60	442	265	11,911	Apr 03 04:21 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Apr 01 '24	Sale	13.23	9,426	124,684	2,485	Apr 03 04:21 PM
Nash Huw M.	COO & CBO	Apr 01 '24	Option Exercise	0.40	50,000	20,000	61,329	Apr 03 04:19 PM
Nash Huw M.	COO & CBO	Apr 01 '24	Sale	13.23	61,329	811,212	0	Apr 03 04:19 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 28 '24	Sale	13.20	5,126	67,668	2,598	Apr 01 04:14 PM
Tulipano Stephen J	CFO	Mar 15 '24	Option Exercise	0.00	13,100	0	24,862	Mar 19 08:36 PM
Tulipano Stephen J	CFO	Mar 19 '24	Sale	6.10	4,116	25,102	20,746	Mar 19 08:36 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 15 '24	Option Exercise	0.00	13,100	0	15,585	Mar 19 08:34 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 19 '24	Sale	6.10	4,116	25,102	11,469	Mar 19 08:34 PM
Nash Huw M.	COO & CBO	Mar 15 '24	Option Exercise	0.00	13,100	0	15,445	Mar 19 08:31 PM
Nash Huw M.	COO & CBO	Mar 19 '24	Sale	6.10	4,116	25,102	11,329	Mar 19 08:31 PM
Kaye Edward M. MD	CEO	Mar 15 '24	Option Exercise	0.00	35,500	0	80,500	Mar 19 08:30 PM
Kaye Edward M. MD	CEO	Mar 19 '24	Sale	6.10	11,150	67,999	69,350	Mar 19 08:30 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 15 '24	Option Exercise	0.00	7,475	0	10,073	Mar 19 08:29 PM
Allan Jonathan	GENERAL COUNSEL & CORP SEC	Mar 19 '24	Sale	6.10	2,349	14,326	7,724	Mar 19 08:29 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 01 '24	Option Exercise	0.60	5,504	3,302	12,485	Mar 05 04:21 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Mar 01 '24	Sale	7.75	10,000	77,469	2,485	Mar 05 04:21 PM
TZIANABOS ARTHUR	Director	Feb 13 '24	Option Exercise	2.19	31,739	69,508	31,739	Feb 15 04:17 PM
Ticho Barry	CHIEF MEDICAL OFFICER	Feb 01 '24	Sale	4.80	10,000	47,991	6,981	Feb 05 04:32 PM
Ticho Barry	Chief Medical Officer	Jan 02 '24	Sale	5.74	10,000	57,352	16,981	Jan 04 04:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

STOK

Stoke Therapeutics Inc

Upgrade your FINVIZ experience